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Systemic inflammation contributes 
to impairment of quality of life in 
chronic pancreatitis
Stuart M. Robinson1,2, Sebastian Rasch  3, Sebastian Beer4, Irena Valantiene5, 
Artautas Mickevicius6, Elisabeth Schlaipfer3, Jelena Mann1,2, Patrick Maisonneuve7, 
Richard M. Charnley1 & Jonas Rosendahl8
Chronic pancreatitis (CP) is a fibrotic disorder of the pancreas leading to clinical sequelae like pain 
and an excess of comorbidity including cardiovascular disease and cancers. The aim of this study was 
to determine the relationship between systemic inflammation and quality of life in patients with CP. 
Patients were prospectively recruited and underwent a quality of life assessment (EORTC QLQ-C30 and 
PAN 28). The serum inflammatory profile was assessed using an MSD 30-plex array. The relationship 
between clinical variables, inflammatory cytokines and quality of life was determined by a GLM-
MANOVA and the individual impact of significant variables evaluated by a second ANOVA. In total, 211 
patients with a median age of 53 years were recruited across 5 European centres. Gender, age, nicotine 
and alcohol abuse were clinical variables associated with altered quality of life. Systemic inflammation 
with high levels of pro-inflammatory cytokines (Eotaxin, IL-1β, IL-7, IL-8, IL-12/IL-23p40, IL-12p70, IL-13,  
IL-16, IP-10, MCP-1, MCP-4, MDC, MIP-1a, TARC, TNFß) was associated with diminished quality of life 
in general and specific domains including pain, physical and cognitive functioning. As conclusion, CP 
is associated with a systemic inflammatory response that has a negative impact on quality of life and 
accelerates aging.
Chronic pancreatitis (CP) is a disease characterised by chronic inflammation in the pancreas which ultimately 
results in organ fibrosis. This process manifests itself clinically in a variety of ways including chronic abdominal 
pain, steatorrhoea, diabetes mellitus, obstructive jaundice and malabsorption of nutrients leading to secondary 
conditions such as osteoporosis1–3. Unsurprisingly CP is associated with diminished quality of life and a high 
socioeconomic burden not only to individuals but also to society as a whole3–5.
Medical co-morbidity is commonplace in patients with CP. In a retrospective registry study in Denmark Bang 
et al. compared the outcome of 11,972 CP patients with 119,720 age and gender matched controls over a 15-year 
period6. They demonstrated that there was a marked excess mortality in patients with CP over the study period 
with a mean age of death in patients of 63.7 years as compared to 72.1 years in controls (p < 0.0001). There was an 
excess of comorbidity in the CP group (78% vs. 38%; p < 0.0001) with diseases including cerebrovascular disease, 
COPD, ulcer disease, diabetes mellitus and chronic renal disease. Further there was an increased risk of malig-
nancy in the CP group (13.6% vs. 7.9%; p < 0.0001)6.
These findings fit with the concept that CP is associated with accelerated biological ageing a process typically 
characterized by the development of frailty, sarcopenia and diseases associated with older age such as cardio-
vascular disease and cancers7. Specifically there is a recognized increase in the incidence of pancreatic ductal 
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adenocarcinoma in patients with CP, especially in the hereditary form of the disease, which is attributed predom-
inantly to the local inflammatory process acting as an oncogenic driver8,9.
While shared risk factors and co-morbidities like smoking and malnutrition contribute to accelerated aging 
in patients with CP, there is also a strong and established association between accelerated ageing and systemic 
inflammation – the so-called inflammageing phenotype. Indeed an elevation in markers of systemic inflamma-
tion e.g. serum IL-6 and CRP occurs during the normal ageing process despite the absence of infection or other 
pathophysiological processes to account for their rise10,11. In a recent systematic review we have demonstrated 
that CP is associated with elevated systemic levels of inflammatory mediators such as IL-6, TNFα, IL-8 and mem-
bers of the IL-1 family12. The aim of the current study was to determine the impact of this systemic inflammation 
on quality of life in patients with CP and thereby determine if inflammageing may be a concept worthy of further 
exploration in this disease.
Materials and Methods
The study was approved by the ethical review board of Technische Universität München (Project 104/15) on 
02/04/2015 and by each of the relevant ethics authorities in the participating centres. The study protocol conforms 
to the ethical guidelines of the 1975 Declaration of Helsinki. Written, informed consent was obtained from each 
patient included in the study.
Patients. Patients presenting with an established diagnosis of CP attending for review at each of the par-
ticipating centres were invited to participate in this study. The presence of CP was defined as per the HaPanEU 
guidelines i.e. either a pain history typical for the disease or, in the absence of pain, the presence of biochemically 
proven pancreatic exocrine insufficiency. In addition all patients were required to have radiological evidence of 
CP and the initial diagnosis had to be at least 2 years prior to recruitment2.
The exclusion criteria for this study were as follows: an active diagnosis of neoplasia or a disease free interval 
of less than five years; patients unable to provide informed consent to participate in the study including those less 
than 18 years of age; patients with Childs-Pugh score B/C liver cirrhosis; patients who were immunosuppressed 
either as a result of disease (e.g. HIV) or active medical treatment (patients with NSAID as pain medication were 
not excluded); patients treated with antibiotic therapy within the last month or with an active infective process; 
patients who had received systemic steroid treatment within the last month; patients with chronic kidney dis-
ease stage 4 or greater (eGFR < 30 ml/min) and those who had received surgical treatment of any form to any 
body-site within the last year.
At the point of recruitment the interviewing doctor completed a study questionnaire and all patients were 
asked to complete the EORTC QLQC-30 and PAN-28 questionnaires. Blood samples were taken for full blood 
count, urea & electrolytes, liver function, CRP and HbA1C. A serum sample was stored for later analysis at −80 °C.
Interpretation of quality of life data. Quality of life was assessed by calculating function or symptom 
scores for each of the domains assessed by the two questionnaires4,13. For both types of score a raw score was first 
calculated as the mean response to each of the component items constituting the domain. For functional scores 
the following equation was then utilised:
= − − ×Functional Score {1 (Raw Score 1)/range} 100
For functional domains a low score implies poorer function and therefore a lower quality of life. In contrast for 
symptom domains the following formula was utilised:
= − ×Symptom Score {(Raw Score 1)/range} 100
For symptom domains a high score implies more severe symptoms and therefore a poorer quality of life.
Assessment of inflammatory response. Using stored serum the concentration of 28 inflammatory 
mediators (Eotaxin, Eotaxin-3, GM-CSF, IFNγ, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17, 
IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-7, IL-8, IP-10, MCP-1, MCP-4, MDC, MIP-1α, MIP-1β, TARC, TNFα, TNF-β, 
VEGF-A) were assessed using a multiplex array according to the manufacturers instructions (Meso Scale 
Diagnostics, Maryland, USA).
To determine the relationship between systemic inflammation and quality of life patients with CP were com-
pared to each other and not to healthy controls. Therefore each of the inflammatory mediators measured was 
categorised as either ‘high’ or ‘low’ based upon the median serum level.
Statistical analysis. To determine the relationship between the measured variables and quality of life meas-
ures we performed a general linear model multivariate analysis of variance (GLM-MANOVA) separately for the 
QLQ-C30 and PAN-28 questionnaires. We assessed the impact of each factor using Wilks λ with p < 0.05 being 
considered significant. To ensure that the associations of measured inflammatory variables were independent of 
key clinical factors (smoking, diabetes mellitus and current alcohol consumption) the analysis was repeated with 
these factors as co-variates14.
Those factors identified as being associated with quality of life on GLM-MANOVA were then entered into a 
second ANOVA to investigate the association between each factor and the quality of life scale items individually 
with post-hoc testing using the Bonferroni correction with a p < 0.05 being considered statistically significant.
Numerical variables are presented as mean (±standard deviation). All statistical analysis was carried out using 
SPSS v. 23 (IBM Corporation, USA).
Any additional data that is not mentioned in the article is provided as supplementary material.
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Results
Across the five participating centres 296 patient were screened for this study, 51 met one or more of the exclusion 
criteria, 30 refused to participate, 3 were discharged before inclusion and 1 patient had an unsure diagnosis of CP. 
Altogether a total of 211 patients were recruited for this study. Patient characteristics are summarised in Table 1.
Quality of life measures. Across the entire study population the mean global quality of life score was 
51.54(±25.38). In the QLQ-C30 questionnaire the lowest function scores were reported for role functioning 
(60.43 ± 35.60), emotional functioning (61.40 ± 35.60) and social functioning (62.51 ± 34.23) and the highest 
symptom scores were reported for pain (50.65 ± 34.86), insomnia (48.22 ± 37.61) and fatigue (47.91 ± 30.72). For 
the PAN-28 questionnaires the highest symptom scores were reported for fear for future health (65.34 ± 33.40), 
bloated abdomen (47.45 ± 37.79) and pancreatic pain (46.90 ± 31.20). Table 2 summarises quality of life scores 
across each domain.
Clinical variables associated with quality of life. Using the GLM-MANOVA we identified that age 
(p = 0.03), gender (p = 0.0001) and current smoking status (p = 0.002) were all associated with quality of life out-
comes in the QLQ-C30 questionnaire (Supplementary Table 1). In the PAN-28 questionnaire gender (p = 0.04), 
being a current drinker (p = 0.001) and the presence of diabetes mellitus (p = 0.04) were also negatively associated 
with quality of life outcomes (Supplementary Table 2).
Subsequent ANOVA analysis revealed that being a current smoker impacted negatively on quality of life across 
a total of 14 domains in the QLQ-C30 quality of life questionnaire. Male gender was associated with poorer cog-
nitive function, increased dyspnoea scores but better digestive function. Older age was associated with increased 
financial difficulties. In the PAN 28 being a current drinker was associated with a higher feeling of alcohol related 
guilt but was associated with less night pain, lower symptom scores for decreased muscle strength and a positive 
impact on body image. The presence of diabetes mellitus was associated with poorer sexual function but less 
alcohol related guilt (Table 3).
Systemic inflammation and quality of life. Mean levels of inflammatory mediators are presented in 
Supplementary Table 3. The most relevant associations of inflammatory mediators with quality of life are pre-
sented in Table 4 and Fig. 1. Supplementary Table 4 displays all associations with quality of life domains and 
inflammatory mediators.
Of the measured inflammatory mediators 3 were associated with an impact on quality of life across both 
QLQ-C30 and PAN-28, these being MDC, IL-7 and IP-10. Across the two questionnaires a high serum MDC 
level was associated with a negative impact across 12 measured quality of life domains including role functioning, 
social functioning, fatigue and insomnia. A high serum IL-7 had a negative impact on a total of 10 quality of life 
domains across the two questionnaires including global quality of life. High IL-7 seemed to be particularly asso-
ciated with a negative impact on domains related to digestive function including nausea and vomiting, diarrhoea 
and indigestion. A high serum IP-10 had a negative impact on quality of life across a total of 4 domains.
High expression of a further 5 inflammatory mediators (IL-8, IL-12/IL-23p40, IL-16, MIP1α and TNFβ) were 
associated with a negative impact on quality of life domains measured by QLQ-C30. Of these high serum levels of 
IL-8, IL-16 and MIP1α were associated with a negative impact on global quality of life. Individually a high serum 
MIP1α had a negative impact across 12 measured domains, IL-16 across 10 domains, IL-8 across 8 domains and 
both IL-12/IL-23p40 and TNFβ on one domain each.
For the PAN-28 questionnaire a high expression of 6 of the measured inflammatory mediators (Eotaxin, 
IL-12p70, IL-13, IL-1β, MCP1, MCP4, TARC) was associated with a negative impact on quality of life. Whilst 
a high serum MIP1β was associated with a negative impact on quality of life this association was lost when the 
GM-MANOVA analysis was adjusted for diabetes mellitus and it was thus not considered further (λ = 0.802; 
p = 0.07, Supplementary Table 2). A high serum MCP4 had a negative impact on 4 of the measured quality of life 
domains. Eotaxin, MCP-1 and TARC impacted on 3 domains each; IL-12p70 and IL-1β on 2 domains each and 
IL-13 on one domain.
Participant Age 53 (19–84) years#
Gender 156 Male/55 Female
Time since initial diagnosis of CP 7 (2–53) years#
Pancreatitis Aetiology
Alcohol
Other
148 (70.1%)
63 (29.9%)
Current Smoker (n = 210)* 108 (51.4%)
Current Drinker (n = 209)* 55 (26.3%)
Diabetes Mellitus (n = 210)* 89 (42.4%)
Pain medication with
NSAID
Mild opioids (WHO class 2)
Potent opioids (WHO class 3)
77 (36.5%)
59 (28.0%)
51 (24.2%)
Pancreatic surgery 40 (19.0%)
Table 1. Summary of patient characteristics. *Numbers in parenthesis represent number of patients with 
complete data for the variable; #Median (range); WHO = world health organisation.
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Discussion
It has been reported in a variety of other diseases that elevated serum inflammatory cytokine levels are associated 
with an impaired quality of life in patients15–17. In this study we have shown that there is a strong link between a 
diminished quality of life and systemic inflammation in patients with CP. Several pro-inflammatory mediators 
are associated with reduced quality of life in general or with worse specific function and symptom scores of the 
QLQ-C30 and PAN 28 questionnaires. While some of the inflammatory mediators were described in recent clin-
ical and pre-clinical studies dealing with this issue, changed serum levels of most of the identified inflammatory 
mediators have not been associated to CP yet12,18. Patients with CP suffer from a diminished quality of life in 
general. Our results indicate three aspects with a particular impact on quality of life: pain as the most prevalent 
symptom, pro-inflammatory mediators involved in fibrosis as well as in accelerated aging.
Amongst the symptom scores pain stands out with an apparently high score. This finding is in accordance 
with previous studies and questions the current analgesic treatment of these patients. Analgesic medication alone 
often does not result in sufficient pain control13,19. Otherwise, it has been demonstrated that smoking influences 
disease progression in chronic pancreatitis as measured by calcifications within the gland and the development 
of diabetes mellitus20. Of the measured clinical variables smoking impacted on 14 individual domains of the 
QLQ-C30 questionnaire including those such as pain and global quality of life. This confirms the results of recent 
publications that also showed that pain and nicotine abuse negatively influence quality of life in patients with 
CP21,22. Whether pain and smoking status are independent variables influencing quality of life as described by 
Machicado et al. or nicotine abuse influences quality of life by its impact on pain still has to be evaluated. The fact 
that smoking cessation might be a potent additive option to treat pain and improve quality of life in those patients 
highlights the need for targeted support for this patient cohort.
Scales Items Mean (SD)
QLQ-C30
Global quality of life Q29,30 51.54 (25.38)
Physical functioning Q1-5 73.33 (24.97)
Role functioning Q6-7 60.43 (35.60)
Emotional functioning Q21-24 61.40 (29.35)
Cognitive functioning Q20,25 72.79 (26.66)
Social functioning Q26,27 62.51 (34.23)
Fatigue Q10,12,18 47.91 (30.72)
Nausea/Vomiting Q14-15 25.09 (31.57)
Pain Q9,19 50.65 (34.86)
Dyspnea Q8 24.43 (31.44)
Insomnia Q11 48.22 (37.61)
Appetite loss Q13 38.37 (37.08)
Constipation Q16 20.65 (29.92)
Diarrhea Q17 22.77 (28.96)
Financial problems Q28 35.50 (36.47)
PAN-28
Pancreatic pain Q31,33,35 46.90 (31.20)
Digestive function Q36,37 45.40 (36.61)
Jaundice Q44,45 14.17 (20.03)
Altered bowel functioning Q46,47 30.47 (28.05)
Body image Q48,51 37.89 (32.48)
Alcohol related guilt Q49,50 21.15 (28.40)
Satisfaction with health care Q55,56 38.85 (35.71)
Sexual functioning Q57,58 38.83 (38.43)
Bloated abdomen Q32 47.45 (37.79)
Night pain Q34 37.75 (36.06)
Taste changes Q38 20.03 (29.99)
Indigestion Q39 36.32 (36.09)
Flatulence Q40 42.79 (33.74)
Weight loss Q41 30.36 (38.67)
Decreased muscle strength Q42 36.50 (34.83)
Dry mouth Q43 38.26 (34.76)
Fear for future health Q53 65.34 (33.40)
Ability to plan ahead Q54 41.62 (37.39)
Table 2. Calculated scores of EORTC QLQ-C30 and PAN28 scales. Q = question.
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In this study we have shown for the first time, to our knowledge, an association between an elevated MIP-1a 
level and poorer quality of life. MIP-1a is primarily described as a chemokine attracting macrophages and neu-
trophils to areas of tissue injury23, indeed MIP-1a is thought to play a key role in attracting macrophages to the 
injured pancreas in murine models of alcohol induced pancreatitis24.
Whilst it may be that MIP-1a is simply a surrogate for pancreatic injury and therefore a diminished quality 
of life the chemokine has been linked with more systemic effects that may also affect quality of life. For example 
elevated serum levels of MIP-1a have been linked to changes in mood and altered cognition and this would fit 
with our finding that MIP-1a was significantly associated with poorer cognitive functioning25,26. There is also 
evidence from animal models of sciatic nerve ligation that MIP-1a contributes to the pathogenesis of neuropathic 
pain although we did not demonstrate an association with pain in the current study27.
Fibrosis is one key element in pathogenesis and progression of CP and driven among others by Il-1328. Also, 
an increased serum MDC level was associated with a negative impact on quality of life across both questionnaires. 
MDC is associated with pulmonary fibrosis and in those patients with idiopathic pulmonary fibrosis, it is associ-
ated with poorer outcomes29,30. Similarly whilst little is known of the role of IL-7 in CP it does play a fundamental 
role in the biology of fibroblast activation. Also IP-10 has been identified as a biomarker of chronic liver disease 
where it promotes inflammation and fibrosis and so may represent a part of the fibrogenic process in CP31,32.
Another area that has not received much exploration to date is the impact of systemic inflammation on the 
development of frailty and ageing. Typically ageing is associated with triggering of the NF-κB, IL-1α, TGF-β and 
IL-6 pathways33. In addition, a senescence associated secretory phenotype has been described and many inflam-
matory mediators identified in this analysis belong to this secretory phenotype. As a negative regulator of TGF-β 
signalling, Il-7 is a component of the senescence associated phenotype34,35. An elevated serum IP-10 level is also 
considered to be a biomarker of the ageing process36. Of the other inflammatory mediators identified as having 
an association with quality of life in this study several are known to be associated with senescence and ageing 
including IL-8, MIP-1a, IL-13, IL-1β and MCP-435. Declines in both physical and cognitive functioning are key 
hallmarks of the ageing process. Il-8 and 16 as well as MDC and MIP-1a are associated with significantly lower 
scores for physical and cognitive functioning.
In addition several of the other inflammatory mediators are associated with poorer quality of life and ageing in 
other diseases. For example an elevated serum IL-16 level is associated with neurocognitive impairment in those 
living with HIV and an elevated serum IL-12p70 is associated with poorer cognitive function in ageing adults37,38.
Predictive 
Variable Questionnaire
Quality of Life  
Domain(s)
Mean Score 
(Male)
Mean Score 
(Female)
Bonferroni 
p-value
Gender
QLQ-C30
Cognitive Function 70.1 80.9 0.01
Dyspnoea 27.4 15.2 0.02
PAN-28 Digestive Function 60.7 42.3 0.02
Mean Score 
(Yes)
Mean Score 
(No)
Older age QLQ-C30 Financial Difficulties 43.7 27.6 0.002
Current Drinker PAN-28
Body Image 27.8 40.7 0.02
Alcohol Related Guilt 28.5 15.3 0.007
Night Pain 29.9 42.7 0.05
Decreased Muscle Strength 28.5 41.3 0.04
Smoker
QLQ-C30
Global Quality of Life 47.8 56.1 0.02
Physical Functioning 67.1 80.3 <0.0001
Role Functioning 50.9 70.4 <0.0001
Emotional Functioning 55.7 68.0 0.004
Cognitive Function 66.5 80.0 <0.0001
Social Function 53.4 72.6 <0.0001
Fatigue 55.5 40.2 <0.0001
Nausea and Vomiting 33.2 16.5 <0.0001
Pain 59.8 42.3 <0.0001
Dyspnoea 30.2 18.2 0.007
Insomnia 59.1 37.9 <0.0001
Appetite Loss 48.8 27.0 <0.0001
Constipation 28.9 12.6 <0.0001
Financial Difficulties 43.0 29.8 0.01
Diabetes mellitus
Sexual Function 31.9 48.1 0.01
Alcohol Related Guilt 11.8 25.5 0.003
Table 3. Impact of patient characteristics on quality of life.
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Predictive 
Variable Questionnaire
Quality of Life 
Domain(s)
Mean Score 
(Low)
Mean Score 
(High)
Bonferroni 
p-value
Eotaxin PAN-28
Bowel Function 24.5 34.9 0.03
Abdominal Bloating 54.6 37.6 0.009
IL-7 QLQ-C30
Global Quality of Life 55.8 48.2 0.04
Fatigue 43.5 53.1 0.03
Nausea and Vomiting 20.0 29.8 0.03
Dyspnoea 19.3 30.4 0.01
Diarrhoea 17.2 27.4 0.01
IL-8 QLQ-C30
Global Quality of Life 56.0 48.3 0.04
Physical Functioning 78.9 67.8 0.002
Cognitive Functioning 77.5 68.3 0.02
Nausea and Vomiting 20.0 29.4 0.04
Dyspnoea 20.1 29.1 0.05
Appetite Loss 32.6 44.0 0.03
IL-12/IL-23p40 QLQ-C30 Dyspnoea 29.6 29.5 0.03
IL-16 QLQ-C30
Global Quality of Life 56.7 47.5 0.01
Physical Functioning 78.4 68.2 0.005
Cognitive Functioning 77.5 68.1 0.02
Fatigue 43.0 53.3 0.02
Nausea and Vomiting 17.2 32.3 0.001
Dyspnoea 19.2 30.1 0.02
IP-10
QLQ-C30 Dyspnoea 20.2 29.3 0.04
PAN-28 Bowel Function 19.7 38.3 <0.0001
MCP-4 PAN-28 Bowel Function 23.8 34.8 0.02
MDC QLQ-C30
Physical Functioning 78.7 67.8 0.003
Fatigue 43.1 53.3 0.02
Nausea and Vomiting 17.2 32.4 0.001
Dyspnoea 17.9 31.5 0.002
Bowel Function 22.0 36.1 0.002
Weight Loss 24.2 39.9 0.02
MIP-1a QLQ-C30
Global Quality of Life 56.5 47.6 0.02
Physical Functioning 80.2 66.2 <0.0001
Cognitive Functioning 78.3 67.2 0.004
Fatigue 40.9 55.6 0.001
Nausea and Vomiting 17.6 32.1 0.001
Dyspnoea 18.6 30.8 0.007
Table 4. Inflammatory mediators and quality of life.
Figure 1. Important aspects of systemic inflammation on quality of life.
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Whether cellular senescence is the cause of the inflammatory pattern seen in those patients with a poorer 
quality of life, or, whether it is merely a consequence of ongoing cellular injury within the pancreas remains to be 
determined although there is evidence that senescence does occur within pancreatic acinar cells and stellate cells 
in patients with CP39,40.
Further studies are needed to evaluate whether the inflammatory mediators are causative for the recorded 
symptoms and changes in quality of life and whether these inflammatory mediators might then qualify as poten-
tial therapeutic targets to treat symptoms and increase quality of life in patients with CP.
Conclusion
This study has demonstrated that diminished quality of life in CP is associated with elevated serum levels of sev-
eral inflammatory mediators which cannot be explained by clinical variables such as smoking status and diabetes 
mellitus. Also inflammatory mediators might be involved in disease progression and accelerated aging in patients 
with CP. It remains to be determined whether this effect is causal or merely a surrogate for ongoing pancreatic 
injury but it is worthy of further exploration given the strong association with CP and poor systemic health. In 
addition, smoking has a strong influence on pain and quality of life in general in those patients.
Data Availability
All data generated or analysed during this study, that are not included in this published article (and its Supple-
mentary Information Files), are available from the corresponding author on reasonable request.
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